On September 25, 2023, Benjamin Hsing published “Artificial Intelligence in Drug Development: Patent Considerations” in IPWatchdog. The following is an excerpt:
The transformative potential of AI, encompassing machine learning and generative capabilities, holds great promise for revolutionizing drug discovery and development. This promising horizon is accompanied by intricate challenges. The implications of patent eligibility, inventorship, ownership, duty of disclosure, and freedom to operate in AI-augmented drug development present multifaceted inquiries that demand careful consideration. Striking a balance between harnessing AI’s capabilities while adhering to patent laws necessitates proactive strategies. Addressing inventorship nuances between human innovation and AI contributions, clarifying the boundaries of patent-eligible subject matter, and charting ownership rights and licensing considerations represent pivotal endeavors.
Click here to access the article.